Recombinant Human RLN Protein，His

RLN (Relaxin) is a peptide hormone belonging to the insulin superfamily, primarily known for its roles in reproductive physiology and various physiological processes. Originally identified for its involvement in pregnancy, RLN facilitates uterine relaxation, aids in cervical ripening, and contributes to the remodeling of reproductive tissues. Beyond reproductive functions, emerging research highlights RLN's potential therapeutic applications in treating cardiovascular diseases, fibrosis, and metabolic disorders. The therapeutic use of RLN is driven by its action on specific receptors, influencing tissue remodeling and angiogenesis. Furthermore, RLN’s ability to modulate inflammation and promote wound healing has attracted considerable interest in regenerative medicine. Despite its promising clinical applications, the complex structure and function of RLN, coupled with its short half-life in circulation, pose challenges for effective therapeutic use. To address these challenges, researchers have focused on the development of recombinant RLN (rRLN) proteins, utilizing advanced genetic engineering techniques for improved stability and efficacy. The study of rRLN not only enhances our understanding of its biological mechanisms but also paves the way for innovative treatments that exploit RLN's multifaceted roles in various physiological and pathological contexts. The ongoing exploration into rRLN encapsulates the convergence of molecular biology, pharmacology, and therapeutics, emphasizing the need for continued research into its various applications and mechanisms of action.